Subscribe To
ORMP / Oramed's oral insulin pill fails; stock is down 72%
ORMP News
By The Motley Fool
January 12, 2023
Why Oramed Pharmaceuticals Stock Is Crashing Today
The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes. more_horizontal
By InvestorPlace
January 12, 2023
Why Is Oramed (ORMP) Stock Down 75% Today?
Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing th more_horizontal
By Market Watch
January 12, 2023
Oramed's oral insulin pill fails; stock is down 72%
Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral ins more_horizontal
By Seeking Alpha
December 7, 2022
Oramed: NASH Biotech Play With Added Bonus
Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary expl more_horizontal
By The Motley Fool
July 12, 2022
Why Oramed Pharmaceuticals Stock Is On Fire Today
The biotech's stock has been ripping higher of late. more_horizontal
By Seeking Alpha
April 14, 2022
Oramed And Oral Insulin: Can This Small Company Really Do It?
Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity. more_horizontal